Search This Blog

Thursday, December 30, 2021

Xeris: FDA OKs Cushing's syndrome med

 FDA approval supported by positive results from the pivotal Phase 3 SONICS and LOGICS studies demonstrating Recorlev to be a safe and effective therapeutic option in the treatment of Cushing's syndrome

FDA decision follows successful completion of acquisition of Strongbridge Biopharma on October 5, 2021

Post-acquisition, the Company is well-positioned to address the needs of Cushing’s syndrome patients in the U.S. who are treated with prescription therapy

Commercial launch of Recorlev is planned for Q1 2022

https://finance.yahoo.com/news/xeris-biopharma-announces-u-fda-213000491.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.